DGNMF.US Diagnamed Holdings Corp.
- Market cap
- USD 2.82M
- P/E
- -
- P/B
- 14.62x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is DGNMF.US undervalued?
Graham numberThe Graham number of Diagnamed Holdings Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Diagnamed Holdings Corp. fundamental analysis
No fundamental analysis for Diagnamed Holdings Corp. yet.
Diagnamed Holdings Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Diagnamed Holdings Corp.
Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It also engages in exploration of Colchester East Natural Hydrogen Project comprising of 2,104 claims located within the Cumberland Basin in Nova Scotia; a…
Full company profileDiagnamed Holdings Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Diagnamed Holdings Corp. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -684K | -1.14M | -1.25M | -741K | -1.49M | -1.83M |
| EBITDA | - | -1.14M | -1.25M | -741K | -1.49M | -1.83M |
| Net Income | -1.95M | -1.13M | -1.28M | -501K | -1.40M | -1.85M |
| EPS | -0.03 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | ||||||
| Total Assets | 2.39M | 1.62M | 662K | 202K | 216K | 331K |
| Total Liabilities | 150K | 370K | 426K | 467K | 666K | 509K |
| Shareholders' Equity | 2.24M | 1.25M | 236K | -265K | -450K | -178K |
| Cash & Short-term Investments | 2.36M | 1.57M | 607K | 162K | 184K | 294K |
| Cash Flow | ||||||
| Operating Cash Flow | -566K | -788K | -1.07M | -445K | -336K | -687K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -566K | -788K | -1.07M | -445K | -336K | -687K |
| Ratios | ||||||
| ROE | -87.0% | -90.9% | -541.8% | - | - | - |
| ROA | -81.5% | -70.1% | -193.0% | -248.4% | -648.5% | -560.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Diagnamed Holdings Corp. dividends
Diagnamed Holdings Corp. has not paid dividends in the last 5 fiscal years.
Who owns Diagnamed Holdings Corp.
- Insiders 13.07%
- Institutions 0.00%
- Public & others 86.93%
- Shares outstanding 132M
- Free float 124M
Diagnamed Holdings Corp. company profile
- Company name
- Diagnamed Holdings Corp.
- Ticker
- DGNMF.US
- ISIN
- CA25245D1033
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Technology
- Fiscal year end
- September
- Address
- 82 Richmond Street East, Toronto, ON, Canada, M5C 1P1
- Phone
- 416 800 2684
- Website
- diagnamed.com
About Diagnamed Holdings Corp.
Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It also engages in exploration of Colchester East Natural Hydrogen Project comprising of 2,104 claims located within the Cumberland Basin in Nova Scotia; and the Timiskaming District of northern Ontario. It has a collaboration agreement with EIREX for the development and commercialization of EIREX's novel modular carbon-free technology that extracts hydrogen from water. Diagnamed Holdings Corp. is headquartered in Toronto, Canada.
Diagnamed Holdings Corp. management
4- Mr. Andre TurmelIndependent Executive Chairman
- Mr. John KaragiannidisPresident, CEO & Director
- Mr. Edward LowInterim Chief Financial Officer
- Mr. Andrew Newbury CPACorporate Secretary